



9640 Medical Center Drive
Rockville, MD 20850

301.517.5556 Telephone
301.315.2438 Facsimile

Contacts: Douglas A Doerfler
President & Chief Executive Officer
MaxCyte, Inc.
(301) 517-5556
dougd@maxcyte.com

Annemarie Moseley, M.D., Ph.D.
Chief Executive Officer
Cognate Therapeutics, Inc.
(408) 616-1032
amoseley@cognatetherapeutics.com

MAXCYTE AND COGNATE THERAPEUTICS COLLABORATE TO DEVELOP PRODUCTS FOR ONCOLOGY

Biotechs Combine Expertise to Develop Non-Viral Gene-Based Therapeutics

Rockville, MD and Sunnyvale, CA – July 16, 2003 – MaxCyte, Inc. and Cognate Therapeutics Inc. announced today a collaboration and license agreement through which Cognate will develop multiple non-viral gene-based products to treat cancer utilizing MaxCyte’s proprietary cell loading system. The agreement provides MaxCyte with up-front and milestone payments, research and development funding, and royalties for products developed from the collaboration. Financial terms of the agreement were not disclosed.

“We are pleased to collaborate with Cognate Therapeutics to bring the company’s impressive stromal cell therapeutics and local cellular delivery technology to the clinic for a new generation of cancer therapies,” said Douglas Doerfler, chief executive officer of MaxCyte. “MaxCyte’s expertise in non-viral gene delivery is accelerating development of gene-based therapeutics with an added degree of safety and flexibility.”

“By working with MaxCyte, Cognate Therapeutics has access to a non-viral gene delivery platform for its therapeutic programs to expedite development of its products,” said Dr. Annemarie Moseley, chief executive officer of Cognate Therapeutics.

About MaxCyte

MaxCyte, Inc., a clinical stage biotechnology company, is commercializing the most efficient and non-viral cell loading technology available today. MaxCyte’s pipeline includes one product in Phase I clinical trials for the treatment of Chronic Lymphocytic Leukemia and numerous late stage preclinical therapeutic candidates in oncology, cardiopulmonary, autoimmune and genetic diseases. MaxCyte is enabling and improving non-viral therapeutic gene transfer, identifying more targeted ways to deliver drugs and accelerating the drug discovery process. Biopharmaceutical research and development applications include high throughput drug discovery, biopharmaceutical production and clinical monitoring. For more information, visit <http://www.maxcyte.com>.

About Cognate Therapeutics

Cognate Therapeutics is a fully integrated biotechnology services company. Cognate's services include management, clinical and regulatory guidance, GMP manufacturing, quality, pre-clinical development, grant writing and funding assistance, intellectual property management, and business and strategic planning. Cognate's clients include Theradigm, Inc., and Vesta Therapeutics, Inc. Theradigm develops neural stem cell and bone marrow stromal cell therapeutics for CNS indications such as stroke, spinal cord injury and traumatic brain injury. Vesta is pioneering the use of liver stem and progenitor cells.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated.

###